Press Releases

Date Headline
2/14/2024
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
 Summary
VANCOUVER, British Columbia , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
2/8/2024
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
 Summary
VANCOUVER, British Columbia , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the  Continue Reading
1/31/2024
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
1/4/2024
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
 Summary
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating  Continue Reading
1/4/2024
Zymeworks Announces Additional Leadership Appointments
 Summary
Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc.  Continue Reading